Gut Bacteria Composition May Determine Melanoma Patients’ Response to Anti-PD-1 Immunotherapy – Melanoma News Today
Melanoma News Today |
Gut Bacteria Composition May Determine Melanoma Patients’ Response to Anti-PD-1 Immunotherapy
Melanoma News Today The presence of a specific bacteria in the gut of patients with melanoma, as well as a greater diversity of gut bacteria, are associated with a better response to anti-PD-1 immunotherapy. Understanding this relationship between a patient’s gut bacteria … |
Telegraph.co.uk |
Terminal cancer patients in complete remission after one gene therapy treatment
Telegraph.co.uk A groundbreaking gene therapy treatment which boosts a patient’s own immune cells has been shown to clear disease from one third of terminal patients. US pharmaceutical company Kite Pharma released results from the first six months of its trial of the … Gene Therapy Shows Promise for Aggressive LymphomaEveryday Health (blog) New gene therapy ‘shrinks tumours like ice cubes’The Times (subscription) Gene therapy extraordinary at fighting blood cancerNew Zealand Herald Mirror.co.uk all 209 news articles » |
Telegraph.co.uk |
Terminal cancer patients in complete remission after one gene therapy treatment
Telegraph.co.uk A groundbreaking gene therapy treatment which boosts a patient’s own immune cells has been shown to clear disease from one third of terminal patients. US pharmaceutical company Kite Pharma released results from the first six months of its trial of the … Gene Therapy Shows Promise for Aggressive LymphomaEveryday Health (blog) New gene therapy ‘shrinks tumours like ice cubes’The Times (subscription) Gene therapy extraordinary at fighting blood cancerNew Zealand Herald Mirror.co.uk –Kite Pharma, Inc. | Investor Relations all 215 news articles » |
Xconomy |
With Eye On FDA, Kite Says CAR–T For Lymphoma Holds Up After 6 Months
Xconomy The patients were treated with a single dose of their own T cells and no other follow-up treatments, according to Kite officials. In CAR–T cell therapy, a patients’ T cells are extracted and genetically modified outside the body to become more … Kite’s CAR–T cancer therapy shows strong results as company races to win FDA approvalSTAT Kite Pharma CAR–T Cancer Therapy Shows Strong, Durable Effect in Lymphoma PatientsTheStreet.com Kite’s shares fly high after cancer drug clears main study goalCNBC Telegraph.co.uk –Endpoints News all 60 news articles » |
|
Single infusion of anti-CD19 CAR T-cells confers high response rate in aggressive non-Hodgkin lymphoma
Healio The ZUMA-1 trial designed to evaluate axicabtagene ciloleucel in patients with chemorefractory aggressive B-cell non-Hodgkin lymphoma met its primary endpoint of overall response rate, according to the drug’s manufacturer. |
Medscape |
Stem Cell Transplantation May Decrease MS-Related Fatigue
Medscape ORLANDO — Along with decreasing inflammatory activity in patients with severe multiple sclerosis (MS), immunoablation and autologous hematopoietic stem–cell transplantation (aHSCT) may reduce MS-related fatigue, new research suggests. |